<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sieber-Frank J</submitter><funding>Hector Stiftung</funding><funding>Else Kröner-Fresenius-Stiftung</funding><pagination>6807-6822</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8495295</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(19)</volume><pubmed_abstract>Rocaglates are natural compounds that have been extensively studied for their ability to inhibit translation initiation. Rocaglates represent promising drug candidates for tumor treatment due to their growth-inhibitory effects on neoplastic cells. In contrast to natural rocaglates, synthetic analogues of rocaglates have been less comprehensively characterized, but were also shown to have similar effects on the process of protein translation. Here, we demonstrate an enhanced growth-inhibitory effect of synthetic rocaglates when combined with glucose anti-metabolite 2-deoxy-D-glucose (2DG) in different cancer cell lines. Moreover, we unravel a new aspect in the mechanism of action of synthetic rocaglates involving reduction of glucose uptake mediated by downregulation or abrogation of glucos</pubmed_abstract><journal>Cancer medicine</journal><pubmed_title>Treatment resistance analysis reveals GLUT-1-mediated glucose uptake as a major target of synthetic rocaglates in cancer cells.</pubmed_title><pmcid>PMC8495295</pmcid><funding_grant_id>2016_A61</funding_grant_id><funding_grant_id>M84</funding_grant_id><pubmed_authors>Kohler R</pubmed_authors><pubmed_authors>Prigge ES</pubmed_authors><pubmed_authors>Kopitz J</pubmed_authors><pubmed_authors>Henkel T</pubmed_authors><pubmed_authors>Krammer PH</pubmed_authors><pubmed_authors>von Knebel Doeberitz M</pubmed_authors><pubmed_authors>Schubert T</pubmed_authors><pubmed_authors>Fischl W</pubmed_authors><pubmed_authors>Kloor M</pubmed_authors><pubmed_authors>Andresen C</pubmed_authors><pubmed_authors>Kalteis S</pubmed_authors><pubmed_authors>Sieber-Frank J</pubmed_authors><pubmed_authors>Stark HJ</pubmed_authors><pubmed_authors>Casari G</pubmed_authors><pubmed_authors>Li-Weber M</pubmed_authors><pubmed_authors>Ahadova A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Treatment resistance analysis reveals GLUT-1-mediated glucose uptake as a major target of synthetic rocaglates in cancer cells.</name><description>Rocaglates are natural compounds that have been extensively studied for their ability to inhibit translation initiation. Rocaglates represent promising drug candidates for tumor treatment due to their growth-inhibitory effects on neoplastic cells. In contrast to natural rocaglates, synthetic analogues of rocaglates have been less comprehensively characterized, but were also shown to have similar effects on the process of protein translation. Here, we demonstrate an enhanced growth-inhibitory effect of synthetic rocaglates when combined with glucose anti-metabolite 2-deoxy-D-glucose (2DG) in different cancer cell lines. Moreover, we unravel a new aspect in the mechanism of action of synthetic rocaglates involving reduction of glucose uptake mediated by downregulation or abrogation of glucos</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2026-05-08T20:46:48.184Z</modification><creation>2022-02-11T12:00:37.558Z</creation></dates><accession>S-EPMC8495295</accession><cross_references><pubmed>34546000</pubmed><doi>10.1002/cam4.4212</doi></cross_references></HashMap>